U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description

Lixisenatide (trade name Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

CNS Activity

CNS Penetrant
2,588

Originator

Zealand Pharma
6

Approval Year

2016
494

Targets

Primary TargetPharmacologyConditionPotency
Glucagon-like peptide 1 receptor
5
Agonist
2,752

Conditions

ConditionModalityTargetsHighest PhaseProduct
Type 2 diabetes mellitus
262
 Palliative
Approved
8,583
ADLYXIN

PubMed

Patents

WO2012156298A1
1

Sample Use Guides

In Vivo Use Guide
The starting dose of ADLYXIN is 10 mcg subcutaneously once daily for 14 days. Increase the dose to the maintenance dose of 20 mcg once daily starting on Day 15.
Route of Administration: Other
In Vitro Use Guide
Unknown
Subunit 0

ACTIVE MOIETY
LIXISENATIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966